For each citation that was shared on social media (LinkedIn, Facebook, or Twitter) with the “@GenScript” tag, the author will be rewarded with a $10 Amazon gift card or 2,000 GS points.

Both chebulagic acid and punicalagin inhibit respiratory syncytial virus entry via multi-targeting glycoprotein and fusion protein

J Virol. 2024-11; 
Yingcai Xiong , Keyu Tao , Tao Li , Yinghui Zhou , Zhaowei Zhang , Weiying Ou , Zhao Wang , Shouchuan Wang , Yayi Hou , Peng Cao , Jianjian Ji
Products/Services Used Details Operation
Peptoid Synthesis CX3C polypeptides and SX3S polypeptides were synthesized by solid-phase polypeptide synthesis (SPPS), provided by GenScript (Nanjing, China); Get A Quote

Abstract

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections, with no currently available small-molecule drugs that are both safe and effective. A major obstacle in antiviral drug development is the rapid emergence of drug-resistant viral strains. Targeting multiple viral compounds may help mitigate the development of resistance. Herein, we conducted a drug screening using the Antiviral Traditional Chinese Medicine Active Compound Library, aiming to identify compounds that simultaneously target the RSV fusion (F) protein, glycoprotein (G), and the host heparan sulfate proteoglycans (HSPGs). From this screening, 10 candidate compounds were identified for their ability to interact wi... More

Keywords

chebulagic acid; fusion protein; glycoprotein; punicalagin; respiratory syncytial virus.